Harrow to Participate in H.C. Wainwright's Ophthalmology Conference

Harrow, a leading North American eyecare pharmaceutical company, announced management participation in H.C. Wainwright's 5th Annual Ophthalmology Conference. CEO Mark L. Baum and CFO Andrew Boll will participate in a fireside chat and Mark will also participate in a panel discussion on novel treatments for front-of-the-eye indications. Both events will be webcast live on the company's website.

Harrow, a leading North American eyecare pharmaceutical company, has announced its management's participation in H.C. Wainwright's 5th Annual Ophthalmology Conference. The event will take place virtually on Wednesday, August 13, 2025.

Mark L. Baum, Harrow's Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in a fireside chat at 8:30 a.m. Eastern time. Additionally, Mark Baum will join a panel discussion on "Novel Treatments for Front-of-the-Eye Indications" at 1 p.m. Eastern time. Both sessions will be webcast live and available on Harrow's website for approximately 90 days following the event.

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. The company aims to make its portfolio of pharmaceutical products accessible and affordable to millions of patients each year.

For more information about Harrow, please visit harrow.com. Contact Mike Biega, Vice President of Investor Relations and Communications, at mbiega@harrowinc.com or 617-913-8890.

[1] https://www.globenewswire.com/news-release/2025/08/06/3128177/0/en/Harrow-to-Present-at-H-C-Wainwright-5th-Annual-Ophthalmology-Conference.html